Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Roberto Leon-Ferre

Breast Oncology · Mayo Clinic College of Medicine

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View

Dr. Neil Iyengar

Breast Oncology · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RSDr. Rebecca Shatsky
    Leading Voice

    Dr. Rebecca Shatsky

    Medical Oncology · Breast Oncology
    University of California San Diego
    rebeccas

    Research

    Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY Clinical Trial

    2026

    Via Research Square (Preprint)

    Research

    Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial

    2026

    Via Research Square

    Research

    Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY Clinical Trial

    2026

    Via Research Square

    Research

    Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

    2025

    Via Nature Communications

    Research

    Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy: Results From Five IO Arms of the I-SPY2 Trial

    2025

    Via JCO Precision Oncology

    Research

    Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial

    2025

    Via JCO Precision Oncology

    Research

    Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium

    2025

    Via Clinical Breast Cancer

    Jul 23, 2025Adaptive Clinical Trial

    Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.

    ​
    ​
    ​+3

    Written by 5 Roon authors & 34 others

    Via Annals of Surgical Oncology
    Jul 24, 2025Clinical Trial, Phase II

    Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.

    ​
    ​
    ​+3

    Written by 5 Roon authors & 31 others

    Via Annals of Surgical Oncology
    Aug 23, 2025Journal Article

    Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.

    ​
    ​
    ​+2

    Written by 4 Roon authors & 29 others

    Via Annals of Surgical Oncology

    Research

    Circulating Tumor DNA Refines Risk Stratification of Neoadjuvant Therapy-Resistant Breast Tumors

    2025

    Via Nature Communications

    Research

    A Phase 1b Study of Zilovertamab in Combination With Paclitaxel for Locally Advanced/Unresectable or Metastatic HER2-Negative Breast Cancer

    2024

    Via Breast Cancer Research

    Research

    A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

    2024

    Via Breast Cancer Research

    Research

    Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

    2024

    Via Nature Medicine

    Research

    Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

    2024

    Via Nature Medicine